Search Results - "Damon, D.B."

Discovery of CP-199,330 and CP-199,331 : Two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity by CHAMBERS, R. J, MARFAT, A, WATSON, J. W, ANTOGNOLI, G. W, CHENG, J. B, DAMON, D. B, KUPERMAN, A. V, LISTON, T. C, MEBUS, C, PILLAR, J. S, SHIRLEY, J. T

“…CP-199,330 (3) and CP-199,331 (4) are cysLT1 receptor antagonists that are equipotent to marketed cysLT1 receptor antagonists zafirlukast and pranlukast, show…”
Get full text

Synthesis and pharmacological profile of two novel heterocyclic chromanols, CP-80,798 and CP-85,958, as potent LTD4 receptor antagonists by Andrews, E.G., Antognoli, G.W., Breslow, R., Carta, M.P., Carty, T.J., Chambers, R.J., Cheng, J.B., Cohan, V.L., Collins, J.L., Damon, D.B., Delehunt, J., Eggler, J.F., Eskra, J.D., Freiert, K.W., Hada, W.A., Marfat, A., Masamune, H., Melvin, L.S., Mularski, C.J., Naclerio, B.A., Pazoles, C.J., Pillar, J.S., Rappach, L.A., Reiche, P., Rusek, F.W., Sherman, H., Shirley, J.T., Sweeney, F.J., Tickner, J.E., Watson, J.W., Wright, C.F.

Get full text

Discovery of CP-199,330 and CP-199,331: Two potent and orally efficacious cysteinyl LT 1 receptor antagonists devoid of liver toxicity by Chambers, R.J., Marfat, A., Antognoli, G.W., Cheng, J.B., Damon, D.B., Kuperman, A.V., Liston, T.C., Mebus, C., Pillar, J.S., Shirley, J.T., Watson, J.W.

“…CP-199,330 ( 3) and CP-199,331 ( 4) are cysLT 1 receptor antagonists that are equipotent to marketed cysLT 1 receptor antagonists zafirlukast and pranlukast,…”
Get full text

Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor-α by Chambers, R.J., Marfat, A., Cheng, J.B., Cohan, V.L., Damon, D.B., Duplantier, A.J., Hibbs, T.A., Jenkinson, T.H., Johnson, K.L., Kraus, K.G., Pettipher, E.R., Salter, E.D., Shirley, J.T., Umland, J.P.

“…Tumor necrosis factor-α (TNF-α) has been implicated as a key mediator in the progression of rheumatoid arthritis. Inhibitors of phosphodiesterase IV (PDE IV)…”
Get full text

Synthesis and pharmacological profile of two novel heterocyclic chromanols, CP-80,798 and CP-85,958, as potent LTD 4 receptor antagonists by Andrews, E.G., Antognoli, G.W., Breslow, R., Carta, M.P., Carty, T.J., Chambers, R.J., Cheng, J.B., Cohan, V.L., Collins, J.L., Damon, D.B., Delehunt, J., Eggler, J.F., Eskra, J.D., Freiert, K.W., Hada, W.A., Marfat, A., Masamune, H., Melvin, L.S., Mularski, C.J., Naclerio, B.A., Pazoles, C.J., Pillar, J.S., Rappach, L.A., Reiche, P., Rusek, F.W., Sherman, H., Shirley, J.T., Sweeney, F.J., Tickner, J.E., Watson, J.W., Wright, C.F.

“…The development of two novel LTD 4 receptor antagonists as clinical candidates for the treatment of asthma is described. The first generation compound,…”
Get full text